PRAX•Praxis Precision Medicines published its Investor Day presentation, targeting FDA action dates of December 27, 2026, for relutrigine and January 29, 2027, for ulixacaltamide. Relutrigine showed an 86% seizure reduction through 18 months, and the company plans to begin three ulixacaltamide studies in 2027.
Praxis Precision Medicines said launch preparations target FDA action dates of December 27, 2026, for relutrigine and January 29, 2027, for ulixacaltamide. Relutrigine extension data showed an 86% seizure reduction from baseline through 18 months, while ulixacaltamide showed improving daily-living response at approximately 95 weeks. Studies of ulixacaltamide in Parkinson's disease, restless legs syndrome and autism spectrum disorder are planned to begin in 2027.
